Home > Insider Trading > Filing (0001103021-20-000053)

Filing Details

Accession Number:: 0001103021-20-000053
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-03-18 16:19:34
Reporting Period:: 2020-03-16

Accepted Time:: 2020-03-18 16:19:34
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1103021	Biodelivery Sciences International Inc	BDSI	Pharmaceutical Preparations (2834)	352089858

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1726687	M. Scott Plesha	C/O Biodelivery Sciences Intl, Inc., 4131 Parklake Ave. Suite 225 Raleigh NC 27612	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-03-16	8,334	$0.00	214,003	No	4	M	Direct
Common Stock	Acquisiton	2020-03-16	8,334	$0.00	222,337	No	4	A	Direct
Common Stock	Acquisiton	2020-03-16	20,833	$0.00	243,170	No	4	M	Direct
Common Stock	Acquisiton	2020-03-16	20,833	$0.00	264,003	No	4	A	Direct
Common Stock	Disposition	2020-03-18	15,000	$3.55	249,003	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	A	Direct
No	4	M	Direct
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2020-03-16	8,334	$0.00	8,334	$0.00
Common Stock	Restricted Stock Units	Disposition	2020-03-16	20,833	$0.00	20,833	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2020-03-19	No	4	M	Direct
0		2021-03-19	No	4	M	Direct

Footnotes

The shares of common stock were acquired by the Reporting Person as a result of the vesting of 8,334 of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2017 under the Issuer's 2011 Equity Incentive Plan, as amended (the EIP).
The shares of common stock were acquired by the Reporting Person as a result of the vesting of 8,334 Performance RSUs granted to the Reporting Person on February 6, 2017 under the EIP, subject to certain performance measures.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of 20,833 of RSUs granted to the Reporting Person on February 18, 2018 under the EIP. The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2021.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of 20,833 Performance RSUs granted to the Reporting Person on February 18, 2018 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures.
The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan.
On March 18, 2018, the Reporting Person sold an aggregate of 15,000 shares of the Issuer's Common Stock at a weighted average price of $3.55 per share. The highest sale price for the Common Stock was $3.64 per share and the lowest sale price was $3.51 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.